Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 201-210 of 456 for breast cancer

Edit search filters
  1. Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

    Rochester, MN

  2. Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

    Rochester, MN

  3. A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  4. A Study to Evaluate Whether Probiotics for Gut Microbiome Will Target Cancer Immune Microenvironment in Breast and Lung Cancer

    Jacksonville, FL

  5. A Study of the Expression and Frequency of Tissue Biomarker Mutations in Breast Cancer that is Resistant or Refractory to Treatment with Trastuzumab and/or Pertuzumab

  6. Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for Locally Advanced or Metastatic ER+/HER2− Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer

    Rochester, MN

  8. A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with GRPR+, ER+, HER2- metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibito

    Rochester, MN

  9. Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)

    Rochester, MN

  10. Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer

    Rochester, MN, Rochester, MN

.

Mayo Clinic Footer